Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Sales of Investments

Cash received from selling or redeeming investments.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments growth accelerates

Q1 FY2026 sales of investments of $5.97M rose 198.3% year over year, ahead of the -33.9% change in trailing-twelve-month sales of investments. Over 3 fiscal years it compounded at -36.1% a year.

Context

  • Sales of investments amounted to 13.7% of revenue in FY2025, down 60.1 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +198.3% holds above the trailing-twelve-month pace of -33.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.97M— QoQ
Last fiscal yearDec 2025
$2M-71.5% YoY
LTMMar 2026
$5.97M-33.9% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+198.3%——
1 year-71.5%——
3-year CAGR-36.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
2M USD
Year-over-year change
-71.5%

Sales of Investments vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 sales of investments of $5.97M is the 2nd largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -33.9% is the 2nd highest of 3, against a peer median of -37.4%.
  • Sales of investments amounts to 40.4% of revenue for LCTX, versus a peer median of 0.0%.
LCTX Competitors Peer median
Sales of Investments for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$143.66M +25.2%——
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$5.97M -33.9%-36.1%40.4%
MESOMesoblast LimitedLTM Jun 2026$0 -100.0%—0.0%
CELUCelularity Inc.LTM Dec 2025$0 ——0.0%
Peer median (excluding LCTX) $0-37.4%—0.0%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.27M)(26.35M)(21.49M)(18.61M)(63.53M)
Depreciation & Amortization873K727K692K609K699K
Deferred Income Tax(6M)0(1.8M)0(5.28M)
Stock-Based Compensation3.52M4.29M4.64M5.08M4.75M
Change in Working Capital21.11M18.67M(10.8M)(8.77M)(4.11M)
Accounts Receivables(857K)50.31M(446K)106K(316K)
Inventory(72K)0000
Accounts Payables21.65M(18.7M)(2.3M)(1.68M)2.27M
Other Working Capital308K(12.94M)(8.06M)(7.19M)(6.07M)
Other Non-Cash Items202K3.73M195K(1.4M)48.55M
Operating Cash Flow(23.56M)1.06M(28.57M)(23.09M)(18.92M)
Capital Expenditures(354K)(413K)(674K)(565K)(522K)
Acquisitions (Net)10.09M45.75M000
Purchases of Investments6.02M(53.41M)(16.4M)(8.76M)(14.94M)
Sales of Investments(6.02M)7.67M63.53M7.02M2M
Other Investing Activities14K(45.75M)000
Investing Cash Flow9.75M(46.16M)46.45M(2.31M)(13.46M)
Debt Repayment(20K)(32K)(54K)(54K)(59K)
Common Stock Issued30.87M148K6.63M35.88M27.03M
Common Stock Repurchased(54K)(17K)(37K)(23K)0
Dividends Paid00000
Other Financing Activities6.14M1.53M(37K)58K(16K)
Financing Cash Flow36.93M1.63M6.42M35.86M26.95M
Effect of Forex Changes(20K)(873K)(250K)(95K)396K
Net Change in Cash23.09M(44.34M)24.06M10.36M(5.03M)
Free Cash Flow(23.92M)646K(29.24M)(23.66M)(19.44M)

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.